Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Pharmaron Beijing Co., Ltd. Class H ( (HK:3759) ) has provided an announcement.
Pharmaron Beijing Co., Ltd. has confirmed that its recently reported manufacturing collaboration with the Chinese subsidiary of a leading global pharmaceutical company is a normal commercial arrangement conducted in the ordinary and usual course of the group’s business. The company emphasized that such collaborations are consistent with its existing operational model, under which it works with a range of partners across sectors to further its business objectives.
The board stated it is not aware of any information that would require disclosure to prevent a false market in its shares or any inside information that must be announced under Hong Kong listing and securities regulations. Investors and shareholders were nonetheless urged to exercise caution when dealing in the company’s securities, signaling a conservative stance on market expectations amid heightened attention to the new collaboration.
The most recent analyst rating on (HK:3759) stock is a Hold with a HK$21.50 price target. To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock, see the HK:3759 Stock Forecast page.
More about Pharmaron Beijing Co., Ltd. Class H
Pharmaron Beijing Co., Ltd. is a China-incorporated joint stock company listed in Hong Kong that operates in the pharmaceutical sector. Through its group subsidiaries, it provides research, development, and manufacturing services, collaborating with multiple partners across different industries to advance its contract-based drug development and production business.
Average Trading Volume: 6,156,050
Technical Sentiment Signal: Sell
Current Market Cap: HK$51.54B
For a thorough assessment of 3759 stock, go to TipRanks’ Stock Analysis page.